Tag: China

China Becomes First Country to Approve Roxadustat for Chronic Kidney Disease Patients with Anaemia

china street
AstraZeneca announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anae...

Sun Pharma & CMSH Signed Licensing Agreement for Generics in China

sun pharma
Sun Pharmaceutical Industries Ltd. announced that one of its wholly-owned subsidiaries has granted an exclusive license to a subsidiary of China Medical System Holdings Ltd. (CMS) to develop and comme...

Novartis Plans to Submit 50 New Drug Applications in China by 2023

The Financial Times reported that Novartis plans to submit 50 new drug applications in China by 2023, which will be split about evenly between innovative and off-patent medicines, according to the com...

Novartis Gilenya® Approved in China

Chinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older. Multiple sclerosis (MS) is ...

Eisai Received New Drug Approval for In-House Developed Anticancer Agent Halaven®

Eisai Co., Ltd. announced that Eisai received New Drug Approval for Eisai’s in-house developed anticancer agent Halaven® (eribulin mesylate) for use in the treatment of patients with locally advanced ...

MacroGenics, I-Mab Announced Agreement to Develop Enoblituzumab in China

MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and I-Mab Biopharma (...

NMPA Granted Priority Review Status to sNDA for Tislelizumab

BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced t...

China to Audit 77 Major Pharmaceutical Companies

China will audit 77 major pharmaceutical companies, including the local arms of Sanofi, Eli Lilly & Co. and Bristol-Myers Squibb Co., after one of its largest listed drugmakers was found to have o...

Jiangsu Hengrui Wave Third Chinese PD-1 to Market

Fast moving Chinese regulators wave third homegrown PD-1 to market Jiangsu Hengrui has secured an OK for its PD-1 drug, marking the fifth PD-1 approval in China and tilting the scale toward homegrown...

GSK Shingrix for the Prevention of Shingles Approved in China

gsk
GlaxoSmithKline plc announced that the National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years or older. Shingrix i...

Sun Pharma Looking for Partner for Chinese Expansion

sun pharma
Sun Pharmaceutical Industries Ltd. is scouting for a partner in China to help it win a larger piece of the world’s second-largest drug market, where the government is on a mission to drive down health...

First Indian-Chinese Working Group on Pharmaceuticals Will Take Place

India will be sending a high-level delegation to the first meeting of the working group on pharmaceuticals, with China, scheduled in Beijing next month. An initiative under the India-China Strategi...

The Russian and the Chinese GMP Inspectorates discussed the prospects for cooperation

In Beijing, a meeting between the Russian state GMP inspectorate and the Chinese regulator CFDI (Center for Food and Drug Inspection) was held. As a follow-up to the meeting, the inspectorate has star...

Eli Lilly Selling Chinese Rights to Two Legacy Antibiotics

Eli Lilly has inked a $375 million deal with China-based Eddingpharm for the rights to two legacy antibiotic medicines and manufacturing facility in Suzhou, China. The sale of off-patent drug asset...

Lonza Experiencing Supply Problems after China Plant Blast

lonza
An explosion at a chemical plant in China that killed 62 people not only exposed weaknesses in China’s safety oversight but it also exposed weaknesses in the global ingredient supply chain. The disrup...

ReNeuron Partners with Fosun Pharma in China

ReNeuron licenses rights to its CTX and hRPC cell therapy programmes to Fosun Pharma for Chinese market. ReNeuron to receive upfront, near term and estimated success-based milestone payments of $104.8...